Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | NR2E1 | Q9Y466 | 2/20 | 0.47 |
| ▸ | HTR5A | P47898 | 1/20 | 0.47 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL997234 | 0.97 | KDM4E (0.47) | KDM4ENR2E1HTR5ANISCHLMNA | |
| SCHEMBL999715 | 0.94 | KDM4E (0.50) | KDM4ENR2E1HTR5ANISCHLMNA | |
| SCHEMBL31280140 | 0.81 | KDM4E (0.50) | KDM4ENR2E1HTR5ANISCHLMNA | |
| SCHEMBL1520201 | 0.75 | KDM4E (0.44) | KDM4ENR2E1HTR5ANISCHLMNA | |
| SCHEMBL9476489 | 0.72 | KDM4E (0.50) | KDM4ENR2E1HTR5ANISCHLMNA | |
| SCHEMBL9845301 | 0.72 | KDM4E (0.44) | KDM4ENR2E1HTR5ANISCHLMNA | |
| SCHEMBL31510878 | 0.71 | HTR2A (0.51) | KDM4ENR2E1HTR5ANISCHLMNA | |
| SCHEMBL31510880 | 0.71 | HTR2A (0.51) | KDM4ENR2E1HTR5ANISCHLMNA | |
| SCHEMBL10019851 | 0.69 | HTR2A (0.57) | KDM4ENR2E1HTR5ANISCHTAAR1 | |
| SCHEMBL30569664 | 0.69 | HTR2A (0.57) | KDM4ENR2E1HTR5ANISCHTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150105415-A1 | TRICYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-04-16 | — | — | US | disclosed |
| US-8952158-B2 | Tricyclic compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
| EP-1829874-B1 | TRICYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2014-02-12 | — | — | EP | disclosed |
| US-20130252993-A1 | TRICYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-09-26 | — | — | US | disclosed |
| US-8476293-B2 | Tricyclic compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20110207700-A1 | TRICYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-7964726-B2 | 1-(1,3-benzodioxol-5-yl)-N-(3,5-dimethylphenyl)-1,9-dihydrospiro[ beta -carboline-4,1'-cyclopropane]-2(3H)-carboxamide; mitochondrial benzodiazepine receptor modulator; digestive system disease caused by stress: irritable bowel syndrome, ulcerative colitis, or Crohn's disease | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-21 | — | — | US | disclosed |
| US-7872133-B2 | Tricyclic heterocycle compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20080114012-A1 | Tricyclic Compound And Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-15 | — | — | US | disclosed |
| EP-1829874-A1 | TRICYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20060154944-A1 | Novel tricyclic heterocycle compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-07-13 | — | — | US | disclosed |
| EP-1637521-A1 | NOVEL TRICYCLIC HETEROCYCLE COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207700-A1 | TRICYCLIC COMPOUND AND USE THEREOF | SI, ALPI, SLC10A2 | KDM4E 2901/4885NR2E1 2696/4885HTR5A 735/4885 |
| US-20060154944-A1 | Novel tricyclic heterocycle compound | CYP11B1, CYP11B2, HCCS | KDM4E 3424/4885NR2E1 1535/4885HTR5A 1979/4885 |
| US-20150105415-A1 | TRICYCLIC COMPOUND AND USE THEREOF | SI, ALPI, SLC10A2 | KDM4E 2901/4885NR2E1 2696/4885HTR5A 735/4885 |
| US-20130252993-A1 | TRICYCLIC COMPOUND AND USE THEREOF | SI, ALPI, SLC10A2 | KDM4E 2901/4885NR2E1 2696/4885HTR5A 735/4885 |
| US-20080114012-A1 | Tricyclic Compound And Use Thereof | SI, ALPI, SLC10A2 | KDM4E 2932/4885NR2E1 2598/4885HTR5A 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.